Who Generates More Revenue? Jazz Pharmaceuticals plc or Cytokinetics, Incorporated

Jazz vs. Cytokinetics: A Decade of Revenue Growth

__timestampCytokinetics, IncorporatedJazz Pharmaceuticals plc
Wednesday, January 1, 2014469400001172875000
Thursday, January 1, 2015286580001324803000
Friday, January 1, 20161064070001487973000
Sunday, January 1, 2017133680001618693000
Monday, January 1, 2018315010001890922000
Tuesday, January 1, 2019268680002161761000
Wednesday, January 1, 2020558280002363567000
Friday, January 1, 2021704280003094238000
Saturday, January 1, 2022945880003659374000
Sunday, January 1, 202375300003834204000
Loading chart...

Infusing magic into the data realm

A Tale of Two Biotechs: Revenue Race from 2014 to 2023

In the competitive world of biotechnology, revenue growth is a key indicator of success. Over the past decade, Jazz Pharmaceuticals plc has consistently outperformed Cytokinetics, Incorporated in terms of revenue generation. From 2014 to 2023, Jazz Pharmaceuticals saw its revenue soar by over 200%, peaking at approximately $3.8 billion in 2023. In contrast, Cytokinetics experienced a more modest growth, with its revenue increasing by around 60% during the same period, reaching a high of about $106 million in 2016 before fluctuating in subsequent years.

This stark difference highlights Jazz Pharmaceuticals' robust market strategy and product portfolio, which have enabled it to capture a larger market share. Meanwhile, Cytokinetics continues to innovate, focusing on niche areas within the biotech sector. As the industry evolves, both companies remain pivotal players, each with unique strengths and challenges.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025